P3 Health Partners Inc. (PIII)
NASDAQ: PIII · Real-Time Price · USD
3.810
-0.070 (-1.80%)
At close: Oct 27, 2026, 4:00 PM EDT
3.930
+0.120 (3.15%)
After-hours: Oct 27, 2026, 4:10 PM EDT
P3 Health Partners Employees
P3 Health Partners had 320 employees as of December 31, 2025. The number of employees decreased by 40 or 11.11% compared to the previous year. That makes P3 Health Partners the 23,364th largest employer in the world and 3,023rd in the United States.
Employees
320
Change (1Y)
-40
Growth (1Y)
-11.11%
Revenue / Employee
$4,696,369
Profits / Employee
-$337,528
Market Cap
27.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 320 | -40 | -11.11% |
| Dec 31, 2024 | 360 | -40 | -10.00% |
| Dec 31, 2023 | 400 | -200 | -33.33% |
| Dec 31, 2022 | 600 | 100 | 20.00% |
| Sep 30, 2022 | 527 | 77 | 17.11% |
| Jun 30, 2022 | 523 | 73 | 16.22% |
| Mar 31, 2022 | 509 | 117 | 29.85% |
| Dec 31, 2021 | 500 | 108 | 27.55% |
| Sep 30, 2021 | 450 | 58 | 14.80% |
| Jun 30, 2021 | 450 | - | - |
| Mar 31, 2021 | 392 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Auna S.A. | 15,254 |
| DocGo | 3,568 |
| WW International | 3,500 |
| Park Dental Partners | 1,212 |
| Concord Medical Services Holdings | 610 |
| AirSculpt Technologies | 363 |
| The Joint | 330 |
| biote | 223 |
PIII News
- 5 days ago - P3 Health Partners Schedules Third Quarter 2026 Earnings Release and Conference Call - Business Wire
- 12 days ago - P3 Health Partners Transcript: The ThinkEquity Conference - Transcripts
- 12 days ago - P3 Health Partners Registration statement: Registration filing - Filings
- 12 days ago - P3 Health Partners files to sell 15.64M shares of Class A common for holders - TheFly
- 15 days ago - P3 Health Partners appoints Millie as Chief Clinical Officer - TheFly
- 15 days ago - P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer - Business Wire
- 1 month ago - FORE Biotherapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 1 month ago - FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions - Business Wire